Cameron Turtle, Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares at $89.14 ($1.4M) on 2026-10-01, disclosed to the SEC on 2026-10-02.
Scheduled sale ($1.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $89.14 | 600 | $53K | 3.9% |
| 2 | $90.10 | 2,683 | $242K | 17.5% |
| 3 | $91.49 | 2,638 | $241K | 17.5% |
| 4 | $92.31 | 3,989 | $368K | 26.7% |
| 5 | $93.37 | 4,990 | $466K | 33.8% |
| 6 | $93.91 | 100 |
| $9K |
| 0.7% |
| Total | $92.01 avg | 15,000 | $1.4M | 100% |
| Filing → |
| SYRE | SELL | 2026-07-02 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $1.1M | — | Filing → |
| SYRE | SELL | 2026-05-01 | $1.1M | — | Filing → |